Search

Concizumab

[L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

Triclabendazole

Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … [FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola

Sevoflurane

[L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. … [L42340] It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient.

Xanomeline

[A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity

Ioxilan

Ioxilan is a tri-iodinated diagnostic contrast agent. … Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant

Arimoclomol

Arimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer. … [L51389] It is also being investigated in amyotrophic lateral sclerosis (ALS) [A264414, A264429] and inclusion body myositis.[A264419]

Tasosartan

Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. … It is used to treat patients with essential hypertension.

Datopotamab deruxtecan

Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]

Zavegepant

[L45505] CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways. … Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.

Aluminium phosphate